We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2326
Aclaris Therapeutics
ACRS
$869M
| $815K | ﹤0.01% |
45,301
+3,435
| +8% | +$55.1K |
|
2327
Amneal Pharmaceuticals
AMRX
$5.79B
| $815K | ﹤0.01% |
152,534
+2,938
| +2% | +$14.8K |
|
2328
Mission Produce
AVO
$1.17B
| $813K | ﹤0.01% |
44,260
+1,750
| +4% | +$34.4K |
|
|
INBX
2329
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $813K | ﹤0.01% |
24,408
+2,431
| +11% | +$74K |
|
2330
Sportsman's Warehouse
SPWH
$46M
| $812K | ﹤0.01% |
46,124
+1,991
| +5% | +$35.3K |
|
2331
Matrix Service
MTRX
$335M
| $808K | ﹤0.01% |
77,207
-11,178
| -13% | -$120K |
|
2332
Bladex Inc
BLX
$2.14B
| $805K | ﹤0.01% |
45,912
+1,450
| +3% | +$23.7K |
|
2333
Boston Omaha
BOC
$436M
| $802K | ﹤0.01% |
20,688
+1,445
| +8% | +$47.7K |
|
|
SP
2334
DELISTED
SP Plus Corporation
SP
| $802K | ﹤0.01% |
26,155
+1,075
| +4% | +$33.4K |
|
|
ACRE
2335
Ares Commercial Real Estate
ACRE
$270M
| $800K | ﹤0.01% |
53,058
+5,519
| +12% | +$83.7K |
|
2336
Rhythm Pharmaceuticals
RYTM
$7.96B
| $800K | ﹤0.01% |
61,287
+275
| +0.5% | +$4.2K |
|
2337
New Fortress Energy
NFE
$101M
| $796K | ﹤0.01% |
28,692
+2,503
| +10% | +$75.5K |
|
|
CPRX
2338
DELISTED
Catalyst Pharmaceutical
CPRX
| $793K | ﹤0.01% |
149,572
+2,181
| +1% | +$11.9K |
|
2339
Transmedics
TMDX
$2.91B
| $793K | ﹤0.01% |
23,955
+1,166
| +5% | +$35.6K |
|
2340
First Community Bankshares
FCBC
$911M
| $790K | ﹤0.01% |
24,895
+340
| +1% | +$10.3K |
|
2341
First Financial Corp
THFF
$969M
| $790K | ﹤0.01% |
18,782
+145
| +0.8% | +$5.81K |
|
|
MRSN
2342
DELISTED
Mersana Therapeutics
MRSN
| $780K | ﹤0.01% |
3,310
+97
| +3% | +$28.3K |
|
2343
Financial Institutions
FISI
$821M
| $778K | ﹤0.01% |
25,398
+725
| +3% | +$21.9K |
|
2344
Mercantile Bank Corp
MBWM
$1.05B
| $778K | ﹤0.01% |
24,290
+700
| +3% | +$21.7K |
|
|
SCU
2345
DELISTED
Sculptor Capital Management, Inc. Class A Common Stock
SCU
| $778K | ﹤0.01% |
27,911
+1,490
| +6% | +$38.7K |
|
|
FRGI
2346
DELISTED
Fiesta Restaurant Group, Inc.
FRGI
| $772K | ﹤0.01% |
70,438
-7,948
| -10% | -$99.8K |
|
2347
Harmony Biosciences
HRMY
$2.24B
| $770K | ﹤0.01% |
20,097
+1,097
| +6% | +$35.3K |
|
2348
Hyster-Yale Materials Handling
HY
$665M
| $770K | ﹤0.01% |
15,329
+335
| +2% | +$20.6K |
|
|
LAND
2349
Gladstone Land Corp
LAND
$360M
| $764K | ﹤0.01% |
33,568
+2,770
| +9% | +$64.6K |
|
2350
Republic Bancorp
RBCAA
$1.95B
| $764K | ﹤0.01% |
15,078
+359
| +2% | +$17.6K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.